Vyant Bio, Inc.
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Latest From Vyant Bio, Inc.
Regulatory review resource-intensive cell and gene therapy licensing applications are rolling toward US FDA along expedited pathways, while complete response letters and missed goal dates start to stack up under pandemic inspection constraints.
New company licenses obicetrapib from Amgen after previous companies’ setbacks in CETP class and works with FDA on a Phase III protocol. BMS buys protein-engineering specialist Forbius.
Private Company Edition: The Alliance for Regenerative Medicine’s half-year report shows the sector raised $10.7bn in the first half of 2020 versus $9.8bn raised in all of 2019. Also, DCVC Bio closed a $350m fund, new incubator opportunities and VC mega-deals for Dyne and Atomwise.
Appointments: Stada, Astellas, Novo Nordisk, Boehringer Ingelheim, Dova, Selvita, Orchard, MannKind, Cancer Genetics
The latest biopharma industry appointments include CEOs for Stada and Astellas, a finance chief for Novo Nordisk and a new president for Boehringer Ingelheim in the US, while Orchard Therapeutics has made a key addition to its scientific advisory board.
- Contract Research Organization-CRO
Laboratory Testing Services
- Esoteric Laboratories
In Vitro Diagnostics
- Chemistry, Immunoassay
- Molecular Diagnostics & Genetic Testing
- Other Names / Subsidiaries
- Bio Type, Inc.
- Cancer Genetics, Inc.
- Gentris Corporation
- Pathwork Diagnostics
- Response Genetics, Inc.
- StemoniX Inc.
- vivoPharm Pty. Ltd.